STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability by Luo, Tuoping, Masson, Kristina, Jaffe, Jacob D., Silkworth, Whitney, Lee, Nathan Ross, Scherer, Christina A., Scholl, Claudia, Frohling, Stefan, Stern, Andrew M., Schreiber, Stuart L., Golub, Todd R., Carr, Steven A

Get full text
Get full text

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia by Kharas, Michael G., Lengner, Christopher J., Al-Shahrour, Fatima, Bullinger, Lars, Ball, Brian, Zaidi, Samir, Morgan, Kelly, Tam, Winnie, Paktinat, Mahnaz, Okabe, Rachel, Gozo, Maricel, Einhorn, William S., Lane, Steven W., Scholl, Claudia, Frohling, Stefan, Fleming, Mark, Ebert, Benjamin L., Gilliland, D. Gary, Jaenisch, Rudolf, Daley, George Q.

Get full text

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells by Scholl, Claudia, Frohling, Stefan, Dunn, Ian F., Schinzel, Anna C., Barbie, David A., Kim, So Young, Silver, Serena J., Tamayo, Pablo, Wadlow, Raymond C., Ramaswamy, Sridhar, Dohner, Konstanze, Bullinger, Lars, Sandy, Peter, Boehm, Jesse S., Root, David E., Hahn, William C., Gilliland, D. Gary, Jacks, Tyler E

Get full text
Get full text

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 by Sandy, Peter, Meylan, Etienne, Reiling, Jan H., Hoersch, Sebastian, Barbie, David A., Tamayo, Pablo, Boehm, Jesse S., Kim, So Young, Moody, Susan E., Dunn, Ian F., Schinzel, Anna C., Scholl, Claudia, Frohling, Stefan, Chan, Edmond M., Sos, Martin L., Michel, Kathrin, Mermel, Craig H., Sabatini, David, Lander, Eric Steven, Jacks, Tyler E

Get full text
Get full text
Get full text